甘李药业
(603087)
| 流通市值：372.65亿 | | | 总市值：399.00亿 |
| 流通股本：5.58亿 | | | 总股本：5.97亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,047,039,079.24 | 2,066,795,642.77 | 984,867,402.61 | 3,045,347,805.11 |
| 营业收入 | 3,047,039,079.24 | 2,066,795,642.77 | 984,867,402.61 | 3,045,347,805.11 |
| 二、营业总成本 | 2,275,937,092.07 | 1,515,608,273.35 | 739,374,819.17 | 2,663,266,844.19 |
| 营业成本 | 725,750,228.68 | 490,877,014.62 | 228,909,866.25 | 766,506,268.87 |
| 税金及附加 | 28,744,855.36 | 18,657,751.86 | 9,066,767.4 | 31,098,356.3 |
| 销售费用 | 978,990,601.81 | 656,481,754.37 | 326,526,305.76 | 1,167,041,098.71 |
| 管理费用 | 196,121,275.25 | 134,027,579.04 | 69,653,246.71 | 255,856,652.47 |
| 研发费用 | 407,861,819.05 | 264,523,560.46 | 130,445,929.06 | 541,045,258.13 |
| 财务费用 | -61,531,688.08 | -48,959,387 | -25,227,296.01 | -98,280,790.29 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 72,066,564.13 | 64,965,330.59 | 46,991,997.72 | 156,612,377.87 |
| 加:投资收益 | 10,823,936.85 | 7,078,197.36 | 3,388,058.82 | 61,249,137.11 |
| 资产处置收益 | - | - | - | 1,866,209.36 |
| 资产减值损失(新) | 876,940.21 | 18,215.12 | - | -15,656,632.99 |
| 信用减值损失(新) | -1,923,291.76 | -1,157,683.72 | -1,891,609.87 | 18,358,447.29 |
| 其他收益 | 15,707,102.52 | 9,513,575.34 | 5,061,170.15 | 27,029,652.52 |
| 四、营业利润 | 868,653,239.12 | 631,605,004.11 | 299,042,200.26 | 631,540,152.08 |
| 加:营业外收入 | 62,344,001.18 | 61,996,279.54 | 61,874,025.33 | 2,848,918.49 |
| 减:营业外支出 | 5,287,205.22 | 2,580,268.68 | 525,341.28 | 4,003,922.48 |
| 五、利润总额 | 925,710,035.08 | 691,021,014.97 | 360,390,884.31 | 630,385,148.09 |
| 减:所得税费用 | 107,370,417.78 | 87,340,442.49 | 48,472,161.29 | 15,721,347.39 |
| 六、净利润 | 818,339,617.3 | 603,680,572.48 | 311,918,723.02 | 614,663,800.7 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 818,339,617.3 | 603,680,572.48 | 311,918,723.02 | 614,663,800.7 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 818,339,617.3 | 603,680,572.48 | 311,918,723.02 | 614,663,846.87 |
| 少数股东损益 | - | - | - | -46.17 |
| 扣除非经常损益后的净利润 | 692,435,647.69 | 487,921,514.17 | 214,645,947.22 | 430,433,077.84 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.38 | 1.02 | 0.53 | 1.04 |
| (二)稀释每股收益 | 1.38 | 1.02 | 0.53 | 1.04 |
| 八、其他综合收益 | -406,764.76 | -21,049.12 | 338,986.22 | 219,526.81 |
| 归属于母公司股东的其他综合收益 | -406,764.76 | -21,049.12 | 338,986.22 | 219,526.81 |
| 九、综合收益总额 | 817,932,852.54 | 603,659,523.36 | 312,257,709.24 | 614,883,327.51 |
| 归属于母公司股东的综合收益总额 | 817,932,852.54 | 603,659,523.36 | 312,257,709.24 | 614,883,373.68 |
| 归属于少数股东的综合收益总额 | - | - | - | -46.17 |
| 公告日期 | 2025-10-31 | 2025-08-08 | 2025-04-25 | 2025-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |